AAPG
Ascentage Pharma Group Internat
Price Chart
No historical data available
Latest Quote
$17.10
-1.18 (-6.44%)
Current Price
| Previous Close | $18.28 |
| Open | $17.78 |
| Day High | $17.78 |
| Day Low | $17.10 |
| Volume | 6,006 |
Stock Information
Note: Financial values converted from CNY to USD
| Shares Outstanding | 93.39M |
| Total Debt | $312.16M |
| Cash Equivalents | $282.50M |
| Revenue | $95.77M |
| Net Income | $-218.88M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.60B |
| EPS (TTM) | $-2.35 |
| Exchange | NGM |
Recent Price History
No history data available. Data will be fetched automatically.
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
đ° Latest News
No news articles available at the moment. Check back later for updates on AAPG.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $7,293,294 | $4,334,575 | $4,551,863 | $3,278,391 |
| Cost Of Revenue | $7,293,294 | $4,334,575 | $4,551,863 | $3,278,391 |
| Total Revenue | $85,561,850 | $146,147,544 | $33,082,564 | $31,253,503 |
| Operating Revenue | $74,407,155 | $139,977,649 | $28,842,773 | $31,253,503 |
| Expenses | ||||
| Interest Expense | $8,058,122 | $9,605,812 | $14,315,500 | $7,866,617 |
| Total Expenses | $264,055,297 | $201,248,887 | $163,132,642 | $157,901,792 |
| Other Income Expense | $-9,897,318 | $162,444 | $509,985 | $848,882 |
| Other Non Operating Income Expenses | $-8,258,122 | $-661,848 | $-208,942 | $-456,036 |
| Net Non Operating Interest Income Expense | $4,181,073 | $-3,966,468 | $-9,485,544 | $-6,416,990 |
| Interest Expense Non Operating | $8,058,122 | $9,605,812 | $14,315,500 | $7,866,617 |
| Operating Expense | $256,762,003 | $196,914,312 | $158,580,779 | $154,623,401 |
| Other Operating Expenses | $-2,160,358 | $-1,352,161 | $-2,884,948 | $-5,007,005 |
| Selling And Marketing Expense | $52,703,429 | $29,209,837 | $29,118,779 | $23,460,656 |
| General And Administrative Expense | $36,703,578 | $27,887,482 | $26,985,992 | $25,423,995 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-185,211,480 | $-60,422,207 | $-137,948,885 | $-131,583,312 |
| Net Interest Income | $4,181,073 | $-3,966,468 | $-9,485,544 | $-6,416,990 |
| Interest Income | $12,239,196 | $5,639,344 | $4,829,955 | $1,449,627 |
| Normalized Income | $-183,946,986 | $-61,071,834 | $-138,503,174 | $-132,922,929 |
| Net Income From Continuing And Discontinued Operation | $-185,211,480 | $-60,422,207 | $-137,948,885 | $-131,583,312 |
| Net Income Common Stockholders | $-185,211,480 | $-60,422,207 | $-137,948,885 | $-131,583,312 |
| Net Income | $-185,211,480 | $-60,422,207 | $-137,948,885 | $-131,583,312 |
| Net Income Including Noncontrolling Interests | $-185,243,968 | $-60,459,018 | $-137,960,063 | $-131,583,312 |
| Net Income Continuous Operations | $-185,243,968 | $-60,459,018 | $-137,960,063 | $-131,583,312 |
| Pretax Income | $-184,209,691 | $-58,905,366 | $-139,025,637 | $-132,216,396 |
| Special Income Charges | $-2,683 | $-7,452 | $596 | $308,197 |
| Earnings From Equity Interest | $46,796 | $-41,878 | $160,358 | $-41,431 |
| Interest Income Non Operating | $12,239,196 | $5,639,344 | $4,829,955 | $1,449,627 |
| Operating Income | $-178,493,447 | $-55,101,343 | $-130,050,078 | $-126,648,289 |
| Gross Profit | $78,268,556 | $141,812,969 | $28,530,701 | $27,975,112 |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-0.80 | $-1.96 | $-2.00 |
| Basic EPS | - | $-0.80 | $-1.96 | $-2.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $-421,498 | $216,542 | $4,281 | $6,732 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-161,577,351 | $-36,280,627 | $-111,379,734 | $-116,319,824 |
| Total Unusual Items | $-1,685,991 | $866,170 | $558,569 | $1,346,349 |
| Total Unusual Items Excluding Goodwill | $-1,685,991 | $866,170 | $558,569 | $1,346,349 |
| Reconciled Depreciation | $12,888,227 | $13,885,097 | $13,888,972 | $9,376,304 |
| EBITDA (Bullshit earnings) | $-163,263,342 | $-35,414,457 | $-110,821,165 | $-114,973,475 |
| EBIT | $-176,151,569 | $-49,299,554 | $-124,710,137 | $-124,349,779 |
| Diluted NI Availto Com Stockholders | $-185,211,480 | $-60,422,207 | $-137,948,885 | $-131,583,312 |
| Minority Interests | $32,489 | $36,811 | $11,177 | $0 |
| Tax Provision | $1,034,277 | $1,553,651 | $-1,065,574 | $-633,085 |
| Gain On Sale Of Ppe | $-2,683 | $-7,452 | $596 | $308,197 |
| Gain On Sale Of Security | $-1,683,309 | $873,621 | $557,973 | $1,038,152 |
| Research And Development | $169,515,354 | $141,169,154 | $105,360,956 | $110,745,755 |
| Selling General And Administration | $89,407,007 | $57,097,319 | $56,104,770 | $48,884,651 |
| Other Gand A | $36,703,578 | $27,887,482 | $26,985,992 | $25,423,995 |
| Diluted Average Shares | - | $11,254,177 | $10,517,857 | $9,824,472 |
| Basic Average Shares | - | $11,254,177 | $10,517,857 | $9,824,472 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
| Other Special Charges | - | - | $-596 | $-308,197 |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-09-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $183,879,587 | $24,366,916 | $-7,410,283 | $44,658,719 |
| Total Assets | $590,697,033 | $390,135,627 | $372,636,819 | $421,797,476 |
| Total Non Current Assets | $151,923,103 | $170,439,348 | $172,312,225 | $177,909,542 |
| Non Current Prepaid Assets | $102,832 | $363,487 | $447,094 | $968,703 |
| Non Current Deferred Assets | $9,211,327 | $11,142,325 | $8,918,331 | $8,091,505 |
| Non Current Deferred Taxes Assets | $4,762,593 | $6,592,549 | $8,918,331 | $8,091,505 |
| Investmentin Financial Assets | $596,125 | $170,045 | $290,760 | $388,823 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $596,125 | $170,045 | $290,760 | $388,823 |
| Goodwill And Other Intangible Assets | $13,506,707 | $15,006,260 | $16,414,307 | $16,244,114 |
| Other Intangible Assets | $9,826,528 | $11,326,081 | $12,734,128 | $12,563,935 |
| Current Assets | $438,773,930 | $219,696,279 | $200,324,595 | $243,887,934 |
| Restricted Cash | $847,243 | $3,671,088 | $3,656,781 | $2,474,069 |
| Prepaid Assets | $21,509,538 | $15,988,078 | $10,527,273 | $10,925,634 |
| Inventory | $4,264,978 | $983,159 | $2,409,389 | $1,408,048 |
| Receivables | $44,879,435 | $14,765,127 | $24,372,579 | $9,163,786 |
| Other Receivables | $216,841 | $914,605 | $989,121 | $96,721 |
| Taxes Receivable | $6,966,915 | $1,459,613 | $1,640,835 | $966,319 |
| Accounts Receivable | $37,695,679 | $12,390,909 | $21,742,623 | $8,100,745 |
| Cash Cash Equivalents And Short Term Investments | $367,272,736 | $184,288,827 | $159,358,573 | $219,916,399 |
| Cash And Cash Equivalents | $367,272,736 | $184,288,827 | $159,358,573 | $219,916,399 |
| Cash Equivalents | $189,063,492 | $51,188,973 | $4,656,930 | $19,374,069 |
| Cash Financial | $178,209,244 | $133,099,854 | $154,701,643 | $200,542,330 |
| Non Current Accounts Receivable | - | $3,879,881 | $1,050,969 | - |
| Other Non Current Assets | - | - | - | $1,162,891 |
| Debt | ||||
| Total Debt | $295,040,096 | $248,658,277 | $267,599,857 | $267,172,435 |
| Long Term Debt And Capital Lease Obligation | $112,852,164 | $132,553,654 | $175,736,368 | $189,917,143 |
| Long Term Debt | $110,629,660 | $129,454,846 | $173,810,287 | $188,554,401 |
| Current Debt And Capital Lease Obligation | $182,187,933 | $116,104,623 | $91,863,489 | $77,255,292 |
| Current Debt | $181,102,538 | $114,697,916 | $90,409,391 | $76,051,418 |
| Other Current Borrowings | $181,102,538 | $114,697,916 | $90,409,391 | $76,051,418 |
| Net Debt | - | $59,863,936 | $104,861,105 | $44,689,420 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $391,857,684 | $349,276,908 | $362,110,441 | $360,894,643 |
| Total Non Current Liabilities Net Minority Interest | $146,943,819 | $175,415,354 | $222,889,424 | $229,575,415 |
| Other Non Current Liabilities | $1,792,996 | $935,022 | - | - |
| Non Current Deferred Liabilities | $32,298,659 | $41,926,678 | $44,425,932 | $34,392,847 |
| Non Current Deferred Taxes Liabilities | $0 | $800,000 | $1,572,131 | $1,810,879 |
| Current Liabilities | $244,913,866 | $173,861,554 | $139,221,017 | $131,319,228 |
| Other Current Liabilities | $293,294 | - | - | $420,566 |
| Current Deferred Liabilities | $8,954,546 | $8,060,358 | $5,724,292 | $3,629,508 |
| Payables And Accrued Expenses | $53,478,094 | $49,696,573 | $41,633,235 | $50,013,861 |
| Payables | $34,960,358 | $37,497,467 | $34,467,512 | $44,665,873 |
| Other Payable | $17,011,029 | $22,356,930 | $22,420,716 | $29,354,695 |
| Total Tax Payable | $2,041,729 | $1,434,724 | $1,250,224 | $1,069,896 |
| Accounts Payable | $15,907,601 | $13,705,813 | $10,796,573 | $14,241,282 |
| Tradeand Other Payables Non Current | - | $0 | $2,727,124 | $5,265,425 |
| Interest Payable | - | - | $155,887 | $57,079 |
| Equity | ||||
| Common Stock Equity | $197,386,294 | $39,373,175 | $9,004,024 | $60,902,833 |
| Total Equity Gross Minority Interest | $198,839,349 | $40,858,719 | $10,526,379 | $60,902,833 |
| Stockholders Equity | $197,386,294 | $39,373,175 | $9,004,024 | $60,902,833 |
| Gains Losses Not Affecting Retained Earnings | $-85,895,978 | $-76,093,295 | $-75,180,479 | $-77,274,815 |
| Other Equity Adjustments | $-59,206,559 | $-57,304,770 | $-55,356,335 | $-53,537,259 |
| Retained Earnings | $-1,045,204,793 | $-859,993,313 | $-799,571,106 | $-661,622,221 |
| Long Term Equity Investment | $4,922,504 | $4,875,857 | $2,533,234 | $2,372,876 |
| Other | ||||
| Ordinary Shares Number | $55,636,617 | $46,978,390 | $43,248,371 | $39,521,007 |
| Share Issued | $55,636,617 | $46,978,390 | $43,248,371 | $39,521,007 |
| Tangible Book Value | $183,879,587 | $24,366,916 | $-7,410,283 | $44,658,719 |
| Invested Capital | $489,118,491 | $283,525,938 | $273,223,702 | $325,508,651 |
| Working Capital | $193,860,064 | $45,834,725 | $61,103,578 | $112,568,706 |
| Capital Lease Obligations | $3,307,899 | $4,505,514 | $3,380,179 | $2,566,617 |
| Total Capitalization | $308,015,953 | $168,828,022 | $182,814,311 | $249,457,234 |
| Minority Interest | $1,453,055 | $1,485,544 | $1,522,355 | $0 |
| Foreign Currency Translation Adjustments | $-26,689,419 | $-18,788,525 | $-19,824,144 | $-23,737,556 |
| Treasury Stock | $441,282 | $1,192 | $3,181,967 | $3,957,079 |
| Additional Paid In Capital | $1,328,890,194 | $975,429,084 | $886,908,217 | $803,730,123 |
| Capital Stock | $38,152 | $31,893 | $29,359 | $26,826 |
| Common Stock | $38,152 | $31,893 | $29,359 | $26,826 |
| Non Current Deferred Revenue | $32,298,659 | $41,126,678 | $42,853,801 | $32,581,968 |
| Long Term Capital Lease Obligation | $2,222,504 | $3,098,808 | $1,926,081 | $1,362,742 |
| Current Deferred Revenue | $8,954,546 | $8,060,358 | $5,724,292 | $3,629,508 |
| Current Capital Lease Obligation | $1,085,395 | $1,406,706 | $1,454,098 | $1,203,875 |
| Current Accrued Expenses | $18,517,735 | $12,199,106 | $7,165,723 | $5,347,988 |
| Investments And Advances | $5,518,629 | $5,045,902 | $2,823,994 | $2,761,699 |
| Investmentsin Joint Venturesat Cost | $4,922,504 | $4,875,857 | $2,533,234 | $2,372,876 |
| Goodwill | $3,680,179 | $3,680,179 | $3,680,179 | $3,680,179 |
| Net PPE | $123,583,609 | $135,001,493 | $142,657,529 | $96,874,071 |
| Accumulated Depreciation | $-42,776,305 | $-33,001,938 | $-22,478,540 | $-10,517,884 |
| Gross PPE | $166,359,914 | $168,003,432 | $165,136,069 | $107,391,955 |
| Leases | $9,051,267 | $6,592,996 | $4,354,397 | $1,153,651 |
| Construction In Progress | $341,878 | $1,131,744 | $1,909,836 | $6,079,583 |
| Machinery Furniture Equipment | $27,806,558 | $27,323,846 | $26,805,515 | $23,131,446 |
| Buildings And Improvements | $125,384,057 | $129,010,286 | $127,953,356 | $72,745,903 |
| Land And Improvements | $3,776,155 | $3,944,560 | $4,112,966 | $4,281,371 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-622,951 | $0 | - | - |
| Finished Goods | $1,106,855 | $575,410 | $1,650,969 | $657,228 |
| Work In Process | $3,781,073 | $407,750 | $758,420 | $750,820 |
| Investment Properties | - | - | $0 | $52,969,450 |
| Other Properties | - | - | - | $96,679,883 |
| Line Of Credit | - | - | - | - |
Fetched: 2026-09-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-179,090,764 | $-20,215,500 | $-116,679,734 | $-132,768,706 |
| Operating Activities | ||||
| Operating Cash Flow | $-174,981,822 | $-16,595,678 | $-108,208,199 | $-97,453,803 |
| Cash Flow From Continuing Operating Activities | $-174,981,822 | $-16,595,678 | $-108,208,199 | $-97,453,803 |
| Operating Gains Losses | $1,470,194 | $-948,286 | $-823,100 | $-2,760,209 |
| Investing Activities | ||||
| Capital Expenditure | $-4,108,942 | $-3,619,821 | $-8,471,535 | $-35,314,904 |
| Investing Cash Flow | $-149,039,050 | $-53,954,547 | $3,267,064 | $-57,319,226 |
| Cash Flow From Continuing Investing Activities | $-149,039,050 | $-53,954,547 | $3,267,064 | $-57,319,226 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,346,647 | $0 | $-882,712 | $-3,990,462 |
| Issuance Of Capital Stock | $343,502,989 | $79,573,772 | $70,056,783 | $0 |
| Financing Cash Flow | $378,554,405 | $46,910,135 | $54,955,441 | $92,290,315 |
| Cash Flow From Continuing Financing Activities | $378,554,405 | $46,910,135 | $54,955,441 | $92,290,315 |
| Net Other Financing Charges | $-1,747,839 | $-1,979,583 | $1,533,532 | - |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $342,156,342 | $79,573,772 | $69,174,070 | $-3,990,462 |
| Common Stock Issuance | $343,502,989 | $79,573,772 | $70,056,783 | $0 |
| Other | ||||
| Repayment Of Debt | $-139,151,568 | $-101,529,511 | $-144,091,956 | $-10,095,827 |
| Issuance Of Debt | $184,943,372 | $79,869,301 | $142,101,345 | $113,802,834 |
| End Cash Position | $178,209,244 | $133,099,854 | $154,701,643 | $200,542,330 |
| Beginning Cash Position | $133,099,854 | $154,701,643 | $200,542,330 | $254,379,440 |
| Effect Of Exchange Rate Changes | $-9,424,143 | $2,038,301 | $4,145,008 | $8,645,604 |
| Changes In Cash | $54,533,533 | $-23,640,090 | $-49,985,694 | $-62,482,714 |
| Interest Paid Cff | $-7,646,498 | $-9,024,739 | $-13,762,742 | $-7,429,061 |
| Proceeds From Stock Option Exercised | $596 | $894 | $1,192 | $2,832 |
| Common Stock Payments | $-1,346,647 | $0 | $-882,712 | $-3,990,462 |
| Net Issuance Payments Of Debt | $45,791,804 | $-21,660,209 | $-1,990,611 | $103,707,007 |
| Net Long Term Debt Issuance | $45,791,804 | $-21,660,209 | $-1,990,611 | $103,707,007 |
| Long Term Debt Payments | $-139,151,568 | $-101,529,511 | $-144,091,956 | $-10,095,827 |
| Long Term Debt Issuance | $184,943,372 | $79,869,301 | $142,101,345 | $113,802,834 |
| Net Investment Purchase And Sale | $-138,470,793 | $-46,532,043 | $14,717,139 | $-19,374,069 |
| Purchase Of Investment | $-138,470,793 | $-46,532,043 | $0 | $-19,374,069 |
| Net Business Purchase And Sale | $-6,459,315 | $-3,802,683 | $-2,980,626 | $-2,980,626 |
| Purchase Of Business | $-6,459,315 | $-3,802,683 | $-2,980,626 | $-2,980,626 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-1,600,000 | $-5,018,629 |
| Purchase Of Intangibles | $0 | $0 | $-1,600,000 | $-5,018,629 |
| Net PPE Purchase And Sale | $-4,108,942 | $-3,619,821 | $-6,869,449 | $-29,945,902 |
| Sale Of PPE | $0 | $0 | $2,086 | $350,373 |
| Purchase Of PPE | $-4,108,942 | $-3,619,821 | $-6,871,535 | $-30,296,275 |
| Taxes Refund Paid | $-4,322 | $0 | $0 | $0 |
| Change In Working Capital | $-21,386,439 | $16,537,407 | $-1,363,040 | $15,560,805 |
| Change In Other Working Capital | $-2,613,562 | $594,635 | $11,183,905 | $-644,411 |
| Change In Other Current Assets | $4,140,686 | $-7,295,082 | $-529,359 | $4,378,540 |
| Change In Payables And Accrued Expense | $19,162,892 | $14,609,091 | $3,794,188 | $12,242,325 |
| Change In Payable | $19,162,892 | $14,609,091 | $3,794,188 | $12,242,325 |
| Change In Account Payable | $2,201,788 | $2,909,240 | $-3,444,709 | $3,680,775 |
| Change In Prepaid Assets | $-12,866,915 | $-2,149,180 | $-1,168,554 | $464,531 |
| Change In Inventory | $-3,904,769 | $1,426,230 | $-1,001,341 | $-822,355 |
| Change In Receivables | $-25,304,770 | $9,351,714 | $-13,641,878 | $-57,824 |
| Changes In Account Receivables | $-25,304,770 | $9,351,714 | $-13,641,878 | $-57,824 |
| Other Non Cash Items | $12,357,377 | $9,593,145 | $14,315,500 | $7,836,066 |
| Stock Based Compensation | $3,110,879 | $3,118,331 | $4,694,933 | $3,294,337 |
| Unrealized Gain Loss On Investment Securities | $169,001 | $123,994 | $104,173 | $1,455,291 |
| Asset Impairment Charge | $622,951 | $0 | $0 | - |
| Depreciation Amortization Depletion | $12,888,227 | $13,885,097 | $13,888,972 | $9,376,304 |
| Depreciation And Amortization | $12,888,227 | $13,885,097 | $13,888,972 | $9,376,304 |
| Amortization Cash Flow | $1,499,553 | $1,617,139 | $1,549,776 | $1,457,824 |
| Amortization Of Intangibles | $1,499,553 | $1,617,139 | $1,549,776 | $1,457,824 |
| Depreciation | $11,388,674 | $12,267,959 | $12,339,196 | $7,918,480 |
| Earnings Losses From Equity Investments | $-46,796 | $41,878 | $-160,358 | $41,431 |
| Net Foreign Currency Exchange Gain Loss | $1,514,307 | $-997,616 | $-241,580 | $402,832 |
| Gain Loss On Sale Of PPE | $2,683 | $7,452 | $-596 | $-308,197 |
| Net Income From Continuing Operations | $-184,209,691 | $-58,905,366 | $-139,025,637 | $-132,216,396 |
| Sale Of Investment | - | - | $14,717,139 | $0 |
| Gain Loss On Investment Securities | - | - | $-420,566 | $-2,896,274 |
| Change In Other Current Liabilities | - | - | - | $0 |
Fetched: 2026-09-01